Interview 31 May 2021 What’s Ahead for European Biotech Startups After Covid? With a tumultuous year behind us, 2021 is set out to spell change for many startups in the European biotech ecosystem. Following the Covid-19 pandemic and Brexit, the European biotech startup landscape has seen some big changes over the course of the past year. Jason Mellad and Dan Rooke, CEO and COO of the Cambridge-based […] May 31, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 28 May 2021 Startup Creator Launched to Fill Europe’s Microbiome Translational Gap With a €49M ($60M) Series A, the French firm eureKARE debuted this month with the goal of priming the translational pump in hot areas where European academics have already made a mark, particularly the microbiome. Strong public funding in Europe often generates great science, but the relative lack of private funding resources leaves more opportunities […] May 28, 2021 - 6 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
Interview 26 May 2021 Immuno-Oncology: From Science Fiction to the Mainstream In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry. We discuss the evolution of the field with experts who have been in it from the very beginning. While immuno-oncology is one of the hottest areas of medicine at the moment, that wasn’t the case 20 years ago. The idea […] May 26, 2021 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2021 Delayed IPOs and Market Drops Batter Biotech Stocks Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […] May 25, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2021 EU Approves Edible Insects for Humans but Roadblocks Remain Europe is seeing a surge of interest in edible insect farming after an EU vote earlier this month greenlit the first insect-derived food product for human consumption. But insect protein pioneers still face other obstacles such as restrictions on what insects can be fed. The approval went to dried yellow mealworm developed by French-based biotech […] May 20, 2021 - 6 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Interview 19 May 2021 Are Biotech Startups Ready for Augmented Reality? Augmented reality is starting to become a part of the manufacturing process of pharma and biotech companies. Paul Haimes, Vice President of Engineering at PTC, discusses the benefits and challenges to implementing this technology across the biotech industry. Augmented reality (AR) is increasingly being used to maintain and optimize biomanufacturing processes, which can bring economic […] May 19, 2021 - 8 minutesmins - By Carlos de Rojas Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2021 Avantium and Carbios Capitalize on Growing Bioplastics Demand As the EU phases out a wide range of single-use plastics this year, investor interest is steadily increasing for adopting easily recyclable or bio-based plastics. In recent weeks, European biotechs Carbios and Avantium have taken big steps towards meeting rising demand. With millions of tons of plastic waste littering the ocean floors, truly solving our […] May 18, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
Expert Advice 17 May 2021 How to Spend Your Biotech Startup’s Money Biotech investment rounds tend to draw big headlines, but experienced players know the real work is done in between them. Avoiding some common pitfalls can make the difference between petering out and pressing on. Managing a biotech startup means always keeping an eye towards the next financing round. But piquing the next investor’s interest requires […] May 17, 2021 - 6 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2021 ADC Approval Buoys Spirits in Cancer Treatment Space The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given a major confidence boost to other European companies in the field as the deal mill picks up speed. Last month, ADC Therapeutics in Switzerland broke into the mainstream when its lead candidate Zynlonta received FDA […] May 11, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 10 May 2021 The Rollercoaster of Repurposing an Arthritis Drug for Covid-19 The Covid-19 pandemic created an opportunity for many biotech companies to repurpose their existing programs into vaccines and treatments for the novel coronavirus. Cyxone’s CEO Tara Heitner and COO Malin Berthold discuss how they approached this shift at their company. Cyxone was founded in 2015 to develop drugs for rheumatoid arthritis and multiple sclerosis. Based […] May 10, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 4 May 2021 Bluebird Bio Withdrawal Raises Gene Therapy Doubts in Europe Last month, the US firm bluebird bio abandoned the sale of its gene therapy Zynteglo in Germany after a pricing dispute with health authorities — a blow that could have repercussions for the rollout of other gene therapies in Europe. Zynteglo was approved in the EU in 2019 as the first-ever gene therapy for the […] May 4, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2021 BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […] April 29, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email